Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The combination of immune checkpoint inhibitors, specifically nivolumab and ipilimumab, is the standard treatment for patients with intermediate or poor-risk clear cell renal cell carcinoma (RCC). While the data is promising, fewer than 50% of patients will experience a partial or complete response to this treatment, and about 20% of patients will see their condition progress despite the regimen. Research indicates that the response to immune checkpoint inhibitors can be influenced by the [gut microbiota](brain://sNjlfTTcrUKKCIgya5_7XQ/GutMicrobiotaImmuneCheckpointInhibitorsI…